# The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

> **NCT00000825** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 72 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00000825
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-05
- **Primary completion:** 2000-03
- **Final completion:** —
- **Target enrollment:** 72 (—)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000825, "The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00000825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*